Direct Oral Anticoagulants in Non‑valvular Atrial Fibrillation with Severe CKD (eGFR < 30 mL/min)
Guideline statements endorse the use of DOACs in patients with non‑valvular atrial fibrillation whose estimated glomerular filtration rate is below 30 mL/min/1.73 m², with a preference for apixaban when eGFR is < 15 mL/min/1.73 m². Dose reductions are required for all agents based on renal function thresholds. [1][2][3][4][5]
Indications for DOAC Initiation
- Patients with non‑valvular atrial fibrillation and eGFR < 30 mL/min/1.73 m² may be offered a DOAC rather than warfarin when bleeding risk is acceptable. [1][2][4]
- Apixaban is specifically recommended as the preferred DOAC in severe CKD (eGFR < 15 mL/min/1.73 m²). [2][3]
Dosing Adjustments by Agent
| DOAC | Standard Dose (eGFR ≥ 50) | Adjusted Dose for eGFR 30–49 | Adjusted Dose for eGFR < 30 | Comment |
|---|---|---|---|---|
| Apixaban | 5 mg bid | 5 mg bid if ≥2 of: age ≥ 80 y, weight ≤ 60 kg, serum creatinine ≥ 1.5 mg/dL | 2.5 mg bid if ≥2 of the above criteria OR eGFR < 30 mL/min | Preferred agent in severe CKD; dose reduction based on clinical criteria rather than eGFR alone [2][3] |
| Rivaroxaban | 20 mg od with food | 15 mg od with food if eGFR 30–49 | 10 mg od with food if eGFR 15–29 | Not recommended when eGFR < 15 mL/min; caution advised [1][4] |
| Edoxaban | 60 mg od | 30 mg od if eGFR 15–50 | 30 mg od if eGFR 15–29 | Avoid if eGFR < 15 mL/min; consider alternative [1][4] |
| Dabigatran | 150 mg bid | 110 mg bid if eGFR 30–49 | 75 mg bid if eGFR 15–29 | Not advised when eGFR < 15 mL/min; increased bleeding risk [1][4] |
Selection Considerations
- Prioritize apixaban in patients with eGFR < 30 mL/min due to favorable safety data. [2][3]
- Evaluate frailty, age, weight, and concomitant nephrotoxic drugs before dose reduction. [2]
- Reserve rivaroxaban, edoxaban, and dabigatran for eGFR ≥ 30 mL/min; avoid initiation when eGFR < 15 mL/min. [1][4]
Monitoring and Safety
- Reassess renal function at least every 3–6 months in patients with eGFR < 30 mL/min. [5]
- Monitor for signs of major bleeding, especially gastrointestinal and intracranial. [5]
- Adjust dose promptly if eGFR declines across threshold boundaries. [5]
Contraindications
- DOACs are contraindicated in patients with eGFR < 15 mL/min for rivaroxaban, edoxaban, and dabigatran. [1][4]
- Warfarin remains an alternative when DOAC use is not feasible. [1]